Cargando…

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales

Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’s class C cephalosporinase (AmpC), they shoul...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonnin, Rémy A., Bernabeu, Sandrine, Emeraud, Cécile, Naas, Thierry, Girlich, Delphine, Jousset, Agnès B., Dortet, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854925/
https://www.ncbi.nlm.nih.gov/pubmed/36671303
http://dx.doi.org/10.3390/antibiotics12010102
_version_ 1784873249835843584
author Bonnin, Rémy A.
Bernabeu, Sandrine
Emeraud, Cécile
Naas, Thierry
Girlich, Delphine
Jousset, Agnès B.
Dortet, Laurent
author_facet Bonnin, Rémy A.
Bernabeu, Sandrine
Emeraud, Cécile
Naas, Thierry
Girlich, Delphine
Jousset, Agnès B.
Dortet, Laurent
author_sort Bonnin, Rémy A.
collection PubMed
description Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’s class C cephalosporinase (AmpC), they should be active on most of the carbapenem-resistant non-carbapenemase-producing Enterobacterales (CR non-CPE). Objectives: Determine the in vitro activity of ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam and comparators against CR non-CPE. Methods: MICs to ceftazidime/avibactam, imipenem/relebactam, meropenem/vaborbactam, but also temocillin, ceftolozane/tazobactam, ertapenem, colistin, eravacycline and tigecycline were determined by broth microdilution (ThermoFisher) on a collection of 284 CR non-CPE (inhibition zone diameter < 22 mm to meropenem). Whole genome sequencing was performed on 90 isolates to assess the genetic diversity as well as resistome. Results: According to EUCAST breakpoints, susceptibility rates of ceftazidime, imipenem, meropenem and ertapenem used at standard dose were 0.7%, 45.1%, 14.8% and 2.5%, respectively. Increased exposure of ceftazidime, imipenem and meropenem led to reach 3.5%, 68.3% and 67.7% susceptibility, respectively. Using the EUCAST clinical breakpoints, susceptibility rates of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam were 88.4%, 81.0% and 80.6%, respectively. Susceptibility rates of temocillin, ceftolozane/tazobactam, tigecycline, eravacycline, and colistin were 0%, 4.6%, 27.8%, 54.9% and 90.1%. MICs distributions with and without the presence of the inhibitor demonstrated a better ability of avibactam and relebactam compared to vaborbactam to restore susceptibility to the associated β-lactam. Conclusions: This study demonstrated the in vitro efficacy of ceftazidime/avibactam, imipenem/relebactam and to a lesser extent meropenem/vaborbactam against CR non-CPE. Moreover, to test all β-lactams/β-lactamases inhibitors combinations without a priori for CRE, non-CPE is crucial since resistance to one of the β-lactam/β-lactamase inhibitor combinations does not predict resistance to another molecule, depending on the resistance mechanisms involved.
format Online
Article
Text
id pubmed-9854925
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98549252023-01-21 In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales Bonnin, Rémy A. Bernabeu, Sandrine Emeraud, Cécile Naas, Thierry Girlich, Delphine Jousset, Agnès B. Dortet, Laurent Antibiotics (Basel) Article Background: Avibactam, relebactam and vaborbactam are β-lactamase inhibitors that proved their efficiency against KPC-producing Enterobacterales. Regarding their inhibitor activity towards Ambler’s class A extended spectrum β-lactamases (ESBL) and Ambler’s class C cephalosporinase (AmpC), they should be active on most of the carbapenem-resistant non-carbapenemase-producing Enterobacterales (CR non-CPE). Objectives: Determine the in vitro activity of ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam and comparators against CR non-CPE. Methods: MICs to ceftazidime/avibactam, imipenem/relebactam, meropenem/vaborbactam, but also temocillin, ceftolozane/tazobactam, ertapenem, colistin, eravacycline and tigecycline were determined by broth microdilution (ThermoFisher) on a collection of 284 CR non-CPE (inhibition zone diameter < 22 mm to meropenem). Whole genome sequencing was performed on 90 isolates to assess the genetic diversity as well as resistome. Results: According to EUCAST breakpoints, susceptibility rates of ceftazidime, imipenem, meropenem and ertapenem used at standard dose were 0.7%, 45.1%, 14.8% and 2.5%, respectively. Increased exposure of ceftazidime, imipenem and meropenem led to reach 3.5%, 68.3% and 67.7% susceptibility, respectively. Using the EUCAST clinical breakpoints, susceptibility rates of ceftazidime/avibactam, imipenem/relebactam and meropenem/vaborbactam were 88.4%, 81.0% and 80.6%, respectively. Susceptibility rates of temocillin, ceftolozane/tazobactam, tigecycline, eravacycline, and colistin were 0%, 4.6%, 27.8%, 54.9% and 90.1%. MICs distributions with and without the presence of the inhibitor demonstrated a better ability of avibactam and relebactam compared to vaborbactam to restore susceptibility to the associated β-lactam. Conclusions: This study demonstrated the in vitro efficacy of ceftazidime/avibactam, imipenem/relebactam and to a lesser extent meropenem/vaborbactam against CR non-CPE. Moreover, to test all β-lactams/β-lactamases inhibitors combinations without a priori for CRE, non-CPE is crucial since resistance to one of the β-lactam/β-lactamase inhibitor combinations does not predict resistance to another molecule, depending on the resistance mechanisms involved. MDPI 2023-01-06 /pmc/articles/PMC9854925/ /pubmed/36671303 http://dx.doi.org/10.3390/antibiotics12010102 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Bonnin, Rémy A.
Bernabeu, Sandrine
Emeraud, Cécile
Naas, Thierry
Girlich, Delphine
Jousset, Agnès B.
Dortet, Laurent
In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title_full In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title_fullStr In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title_full_unstemmed In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title_short In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
title_sort in vitro activity of imipenem-relebactam, meropenem-vaborbactam, ceftazidime-avibactam and comparators on carbapenem-resistant non-carbapenemase-producing enterobacterales
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854925/
https://www.ncbi.nlm.nih.gov/pubmed/36671303
http://dx.doi.org/10.3390/antibiotics12010102
work_keys_str_mv AT bonninremya invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT bernabeusandrine invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT emeraudcecile invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT naasthierry invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT girlichdelphine invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT joussetagnesb invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales
AT dortetlaurent invitroactivityofimipenemrelebactammeropenemvaborbactamceftazidimeavibactamandcomparatorsoncarbapenemresistantnoncarbapenemaseproducingenterobacterales